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First experience with the Edwards 
SAPIEN transcatheter aortic valve 
implantation (TAVI)
Data from the Western Cape, South Africa
Johannesburg, Cape Town and Durban. We report on the experi-
ence of the Cape Town team from October 2009 until July 2011.
METHODS
The heart team
Our team consists of 2 cardiologists, 2 surgeons, 2 anaesthesiolo-
gists and an echocardiography expert.  Patients are screened by the 
cardiologists as well as the surgeons. After assessment they are 
discussed and approved by the team as a whole. A significant 
percentage of our cases are referred by cardiothoracic surgeons 
outside of the team, who have declared the patients inoperable or 
very high risk candidates for open valve replacement. All members 
of the team are present during all implants.
Patients
Patients were accepted for the procedure only if they fulfilled the 
indications for which the Edwards device received CE-mark 
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WITH TAVI IN 
SOUTH AFRICA
INTRODUCTION 
It is well established that the treatment of choice for severe 
symptomatic aortic valve stenosis is valve replacement. Since the 
first surgical implantation in 1960,(1) this procedure has gained a 
multitude of evidence to support its use with an estimated one 
million implants to date. In high volume centres, 30-day mortality 
rates as low as 4% have been reported.(2-4) Despite this, up to a 
third of patients are not even referred for valve replacement due to 
perceived high risk.(5) This has lead to a search for less invasive 
alternatives. Alain Cribier did the first transcatheter aortic valve 
implantation in 2002(6) and this was followed by huge interest in the 
field. The Cribier-EdwardsTM (Edwards LifesciencesTM, Irvine, 
California) valve received CE-mark accreditation in 2007 and to 
date an estimated 18 000 of these valves (and subsequently the 
improved Edwards SAPIENTM and SAPIEN XTTM valves) have been 
implanted.
The first transcatheter aortic valve implants (TAVI) in South Africa 
were implanted in October 2009 by 3 teams, one each in 
Background: Transcatheter aortic valve implantation 
(TAVI) is an exciting new technology that was launched in 
South Africa in October 2009 for the treatment of aortic 
stenosis in patients at high risk for conventional surgery. 
We report our initial experience with TAVI in the 
Western Cape, South Africa.
Methods: 70 patients with severe symptomatic aortic 
stenosis underwent TAVI with the Edwards SAPIEN device 
(26 via transapical approach and 44 via transfemoral) at 
Panorama and Vergelegen Mediclinic hospitals in the 
Western Cape. All implants were performed by a team 
consisting of 2 cardiothoracic anaesthesiologists, 2 cardio-
thoracic surgeons, 2 cardiologists and an echo expert.
Results: Patients were at high risk with a mean age of 80 
years and a mean logistic EuroSCORE of 26. The acute 
procedural success rate was 97% with two acute deaths. 
At 30 days, there were a total of 5 deaths. Major vascular 
complications were seen in 6 cases (9%). Only one stroke 
was seen during the follow-up period.
Conclusions: With a multidisciplinary team approach and 
careful patient selection, TAVI can be performed by a high 
volume centre in South Africa with results comparable to 


















accreditation: They had to have a clear indication for aortic valve 
replacement (symptomatic severe aortic stenosis with a valve area 
of less than 0.8cm2 and a mean gradient of greater than 40mmHg) 
but deemed too high risk for operative aortic valve replacement 
(log EuroSCORE >20 or STS score >10) or a contra-indication for 
open valve replacement (e.g. porcelain aorta). All patients provided 
written informed consent. Contra-indications include: dominant 
aortic regurgitation; bicuspid aortic valve; aortic annulus size 
unsuitable; unprotected left coronary obstruction likely; and 
excessive frailty.
Screening
Screening was performed by at least a cardiologist and a surgeon. 
The reasons for turning patients down for TAVI included poor 
general health (opinion of more than one team member); insufficient 
symptoms; conventional surgery was a realistic possibility; the aortic 
annulus measured <18 or >26mm (as delineated by TEE); and 
refusal by medical aid to fund the procedure. 
Patients underwent transthoracic echocardiography (TTE) to 
assess severity of disease as well as annulus size measurement and 
suitability of the landing zone of the prosthesis. Recent coronary 
angiogram was required, but no coronary intervention or infarction 
was allowed within the month preceding the TAVI. Coronary 
revascularisation was performed only if deemed to be clinically 
relevant (generally, this implied the presence of regular angina). The 
ileo-femoral arteries were assessed by conventional angiography 
or CT scan. Transfemoral implantation was the preferred route, 
unless ileo-femoral anatomy was unfavourable due to tortuosity, 
inadequate calibre and extensive calcification.
CT scan of the aortic root was performed in some of the patients 
to assess the annulus size. This modality tends to oversize the 
annulus, requires extra contrast and local expertise is limited. We 
therefore performed it only in a limited number of cases.
The final decision on the valve size was made with an annulus 
measurement using transoesophageal echocardiography (TEE). 
The procedures
Although the techniques for transfemoral and transapical aortic 
valve implantation have been described previously,(7) certain detail 
is retained in this report as it is required to put the complications 
and outcomes in perspective.
All procedures were performed in the cardiac catheterisation 
laboratory, with equipment for cardiopulmonary bypass and 
sternotomy/thoracotomy on standby. Patients were preloaded 
with aspirin (325mg) and after arterial access was obtained, loaded 
with 5 000 IU of heparin. Aspirin (75-150mg) was continued 
indefinitely. We implanted the Edwards SAPIENTM bovine valve 
using the RetroFlex-IITM delivery system (Edwards LifesciencesTM, 
Irvine, California) for transfemoral procedures and the AscendraTM 
transapical catheter (Edwards LifesciencesTM, Irvine, California) for 
transapical procedures.  From November 2010 (case number 38) 
onwards cases were performed using the Edwards SAPIEN XTTM 
device and the NovaflexTM (Edwards LifesciencesTM, Irvine, 
California) delivery system.
All cases were done under general anaesthesia to facilitate 
continuous TEE monitoring. Due to the large calibre catheters (24 
French for the 26mm and 22 French for the 23mm Edwards 
SAPIEN valve and 19 and 18 French respectively for the 26mm and 
23mm SAPIEN XT valve), we opted to do surgical arterial cut 
down in the groin. An Amplatzer extra-stiff guide wire was passed 
over the aortic valve. A 20-22mm balloon was used to pre-dilate 
the aortic valve under rapid ventricular pacing. 
The Edwards SAPIEN device was then positioned fluoroscopically 
and deployed with balloon inflation under rapid ventricular pacing. 
Immediate success was assessed with supra aortic contrast injection 
as well as with TEE. The puncture site in the groin was closed 
surgically and the result of this closure was assessed with a contrast 
injection through the pigtail catheter in the contralateral groin. 
The technique for the SAPIEN XTTM implantation is similar except 
that the valve is mounted on the delivery catheter, behind the 
balloon. Once exited from the insertion sheath into the abdominal 
aorta, the balloon is pulled back into the crimped valve and clicks 
into place. The mounted valve is then advanced further up the 
aorta.
For the transapical approach, a left mini-thoracotomy was made 
with liberal infiltration with long acting local anaesthetic. The left 
ventricular apex was exposed and pre-closed with plegetted purse 
string sutures. After puncture of the left ventricular apex, the rest of 
the procedure is largely the same as for transfemoral approach, 
except that the valve is mounted in the opposite orientation on the 
balloon catheter.
Data collection
An echocardiogram was performed prior to discharge and patients 
were then seen at 30 days and where applicable, 6 months and 1 
year. We will report only the 30 day data.
8Transthoracic echocardiography was performed before hospital 
discharge and then at 30 days and 1 year at the implantation centre. 
Aortic valve area was calculated with the continuity equation (via 
the velocity-time integral method) from data derived before and 
after device implantation. 
Measurement of the left ventricular outflow tract for calculations of 
aortic valve area was performed with 2-dimensional imaging in a 
zoomed-up parasternal long-axis view. For patients located geo-
graphically far from Cape Town and unable to return to the 
implantation centre for further studies, these measurements were 
undertaken by an experienced local service.
Aortic incompetence was classified as para-valvular or valvular and 
graded as none, trivial, moderate and severe.
Study end-points
We assessed each patient for any complication but focussed on 
the following outcomes: complications (including stroke, major 
vascular complications requiring acute intervention or blood 
transfusion; conduction abnormalities requiring permanent pacing; 
renal failure requiring dialysis) procedural success rate; 30-day 
mortality; and New York Heart Association functional status after 
the procedure. For vascular access complications, stroke and 
bleeding, we used VARC-definitions.(8)
Statistical analysis
P-values for differences in outcomes were calculated using the 
Mann-Whitney U equation (unless stated otherwise) and a value of 
≤0.05 was considered significant.
RESULTS
Baseline characteristics
Seventy patients were included in the study cohort. This represented 
approximately a third of the total number screened. Unfortunately 
accurate screening statistics were not recorded by all the practices 
involved, preventing us from analysing the outcome in patients not 
accepted for TAVI. 
Of the 70 patients undergoing TAVI, 26 received a transapical valve 
and 44 transfemoral. The rate of transfemoral usage increased 
significantly after the introduction of the lower profile SAPIEN XT 
valve (from 50% transfemoral with the larger device to 72% with 
the SAPIEN XT device).
FIRST EXPERIENCE WITH TAVI IN SOUTH AFRICA
TABLE 1: Patient baseline characteristics 
*Expressed as a percentage of the total number of cases for this particular approach (transapical or transfemoral). TA: transapical, TF: transfemoral.
Patient baseline characteristics Total (n=70) Transapical (n=26) Transfemoral (n=44) P-value (comparing TA to TF)
Age (range) 80 (63-92) 77 82 0.01 
Male sex, n (%) 31 (46) 19 (73*) 12 (27*) 0.5 
History of CABG, n (%) 28 (40) 15 (55*) 13 (30*) 0.2 
History of chest radiation, n (%) 1 (1.4) 0 1 (2*) 0.4 
History of peripheral vascular disease, n (%) 15 (22) 12 (46*) 3 (7*) 0.0005 
History of COPD, n (%) 31 (41) 8 (31*) 23 (52*) 0.6 
History of previous cancer, n (%) 10 (14) 2 (8*) 8 (18*) 0.6 
Prior permanent pacemaker, n (%) 15 (22) 6 (23*) 9 (20*)  
Porcelain aorta, n (%) 7 (10) 7 (10*) 0 0.003 
Logistic EuroSCORE (range) 26.4 (9-55) 26.5 (15-39) 26.3 (9-55) 0.72 
NYHA functional class:     
   I 0 0 0  
   II 11 2 9  
   III 40 16 24  



















Coronary revascularisation was not required in any patient after 
referral to our team although 3 patients had PCI procedures done 
in the last 6 months prior to referral to us.
Patients were old (mean age was 80) and had high predicted 
mortality (average logistic EuroSCORE was 26.6) (see Table 1). Of 
the 12 patients with a EuroSCORE below 20, all had either a STS 
score >10 and or had absolute contra-indications to surgery. 
A few of these deserve special mention: 
 ■ Patient 16 had a CT scan that showed extensive circumferential 
calcification of the thoracic aorta which excluded cross 
clamping;
 ■ Patient 25 had a previous attempt at aortic valve replacement 
but at operation, cross clamping of the aorta was impossible 
due to calcification;
 ■ Patient 31 was on long term immune suppressants for 
rheumatoid arthritis and was turned down for surgery by an 
independent surgeon due to frailty and fear of poor wound 
healing;
 ■ Patient 29 had a EuroSCORE over 20, but deemed an operative 
candidate at another institution. She had received previous 
radiation to her thorax for breast cancer. An open aortic valve 
replacement was attempted but abandoned after a lengthy 
effort due to hostile thorax.
Procedural outcomes
Procedural success was achieved in all but 2 patients (97%). Both 
patients died acutely (see under Complications below). Valves 
were placed successfully in all patients who survived the initial 
procedure. See Table 2 for detail. 30-day mortality was 7.1% in a 
cohort with a predicted 30-day mortality of 26% (according to log 
EuroSCORE). In an effort to delineate a potential learning curve, 
we compared procedural parameters for the first half of our 
experience (cases 1-35) with the second half (cases 36-70). This is 
delineated in Table 3.
Complications
Several complications occurred, underlining how frail these patients 
are. They include ileus with aspiration; Stevens-Johnson syndrome 
TABLE 2: Procedural details and immediate outcomes
*Expressed as a percentage of the total number of cases for this approach (transapical or transfemoral). #Compared to MR grade pre-TAVI. TA: transapical, TF: transfemoral.
 Total (n=70), n (%) Transapical (n=26), n (%*) Transfemoral (n=44), n (%*) P-value (comparing TF to TA)
Implanted valve size     
   23mm 38 (54) 14 (54) 24 (55)  
   26mm 32 (46) 12 (46) 20 (45)  
Valve-in-valve 0 0 0  
Conversion to open AVR 0 0 0  
Average procedure time, min (range) 84.7 (45-200) 83 (60-200) 65 (45-140) 0.61 
Contrast use, average (range) 112ml (40-325) 95 (60-189) 119 (40-325) 0.21 
Acute procedural success, n(%) 68 (97) 25 (96) 43 (98)  
Post-implant AR> grade 1, n (%) 9 (13) 1 (4) 8 (18) 0.3 
Post-implant AR> grade 2 0 0 0  
Mean MR grade     
   pre-TAVI 1.5 1.6 1.4  
   post-TAVI 1 1 1 0.014#  
Hospital stay (days)     
   Intensive care 3.4 3.8 2.9 0.07 
   High care unit 4.2 5 3.5 0.02 
   Ward 2 2.7 1.5 0.02 
Time to extubation (hrs) 6.2 13.2 1.3 <0.01
10
due to antibiotics; retropharyngeal haematoma from central venous 
cannulation (with inadvertent puncture of the carotid artery); and 
lower respiratory tract infection. Major complications are listed in 
Table 4. Vascular access related complications were frequent 
(occurred in 15% of cases) but were not associated with any acute 
fatality.
We experienced 5 fatalities within 30 days of the procedure:
1.  Patient 20 was an 88-year-old female with a log EuroSCORE of 
34. Her peripheral vessels were diseased but of adequate 
calibre for the 24 French delivery system. Her implant went 
without problems but 7 days after the implant, she developed 
acute arterial occlusion of the contralateral femoral artery. This 
culminated in an ischaemic leg and acute renal failure.
2.   Patient 37 was a 92-year-old lady who was still working full 
time. She received a successful implant, but a few hours after 
the procedure, she sat up to have lunch. This was promptly 
followed by haemodynamic collapse due to the 6 French 
temporary pacing wire used perforating her right ventricle. 
She died despite immediate diagnosis and treatment of this 
complication. We have since then adopted the use of 5 
French pacing wires only.
3.  Patient 48 was transferred from another institution with 
diabetes, obstructive jaundice, pre-renal failure, previous pul-
monary embolism and critical AS. He was deemed too ill for 
TAVI and received a balloon aortic valvuloplasty. Despite the 
successful valvuloplasty, his condition did not improve 
dramatically and a successful TAVI was performed a week later. 
He however remained unwell and died 21 days later of multi- 
organ failure.
4.  Patient 57 had a previous history of alcohol abuse and poor 
wound healing (with sternal dehiscence after bypass surgery 10 
years prior). He was done via a transapical approach because 
of a horizontal ascending aorta. After needle puncture of his 
left ventricular apex, the ventricle developed a tear that could 
not be contained. This lead to eventual institution of peripheral 
extra corporeal circulation but the tearing could not be 
contained despite prolonged surgical intervention. 
5.  Patient 58 was an 80-year-old lady who had a device inserted 
from a femoral approach. After balloon valvuloplasty, the 
device was placed in the left ventricle but on TEE, extensive 
oscillating tissue attached to the device was seen. The activated 
clotting time at this stage was >300 and we deployed the valve. 
The patient developed extensive embolisation down her 
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TABLE 4: Major complications at 30 days 
*Expressed as a percentages of the total number of cases for this particular approach (transapical or transfemoral). P-values calculated with the Fisher-exact formula. 
VARC: Valve Academic Research Consortium,(8) TA: transapical, TF: transfemoral.
Major complications at 30 days Total (n=65), n (%) Transapical (n=26), n (%*) Transfemoral (n=44), n (%*) P-value (comparing TA to TF)
Death 4 (6) 1 (4) 3 (6.8) 0.05
Stroke 1 (1.4) 1 (4) 0 0.33
Permanent pacemaker 2 (3) 0 2 (5) 0.17
Renal failure requiring dialysis 0 0 0  
Vascular access complications      
   Major (VARC defi nition) 6 (9) 3 (11.5) 3 (6.8) 0.8
   Minor (VARC defi nition) 4 (6) 0 4 (9) 0.09
Major bleeding (VARC defi nition) 4 (6) 3 (11.5) 1 (2.5) 0.6
TABLE 3: Learning curve 
*Denotes patients discharged from hospital with a functional valve.
Column 1 1st 35 cases 2nd 35 cases 
Procedure time (min) 93.42 68.83
Screening time (min) 16.59 13.79
Time to extubation (hrs) 10.09 1.28
ICU stay (days) 3.97 2.78



















coronaries. This was aspirated, she was thrombolysed and the 
left main was stented. After initial recovery, she deteriorated 
again and we could not resuscitate her successfully. A medico-
legal autopsy was performed but the result was not at our 
disposal.
Renal failure requiring dialysis was not seen, despite a mean contrast 
usage of 112ml. This was likely due to good renal function prior to 
the procedure with a mean serum creatinine level of 110umol/l 
(range 60-254). 
Echocardiographic assessment revealed that the mean gradient 
across the aortic valve fell from 54 to 11.6mmHg (see Figure 1). 
The mean AR grade remained low at 1 post op and 13% of cases 
had grade 1 or 2 AR but no cases with >grade 2 AR. 
Most patients experienced significant symptomatic relief as depicted 
in Figure 2.
The purpose of this study is to describe the short term outcome of 
the procedures but we do have access to 1-year mortality follow 
up data on 29 patients: 4 of them (14%) have died. Of these, only 
one was procedural. The others occurred more than 30 days post-
procedure. These patients had an average log EuroSCORE of 35% 
and an average age of 85 which puts them at the higher risk end of 
the cohort as a whole.
DISCUSSION 
Transcatheter aortic valve implantation has grown rapidly since the 
first implants by Cribier. The Edwards SAPIEN bioprostheses has 
now been approved for clinical use in the European Union and 
preliminary guidance for its use has been published by the National 
FIGURE 1: Change in mean gradient across the aortic valve 
(AV gradient) and aortic valve area calculated by echocardio-
graphy (AVA) prior to TAVI, immediately after TAVI and 30 days 
post-TAVI.
FIGURE 2: Most patients experienced signifi cant improvement 
in symptoms of dyspnoea. The blue bars denote New York Heart 
Association functional class pre-TAVI and yellow post-TAVI.
FIGURE 3: Predicted 30 mortality (log EuroSCORE in blue) 
compared to actual 30 day mortality (%, in yellow) across different 
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Institute of Clinical Excellence, the European Association of Cardio-
Thoracic Surgery, and the European Society of Cardiology.
This emphasises that these procedures should only be offered  to 
patients at high risk for conventional surgery as conventional surgery 
has more data to support its use and safety. Patient selection 
remains a problem and the currently used EuroSCORE tend to 
overestimate the risk, while the Society of Thoracic Surgeons’ score 
system underestimates it. Although we could not demonstrate it 
with formal risk assessment scores, it is our opinion that patients on 
the extremely high risk end of the spectrum are also not ideal 
candidates for TAVI. A multidisciplinary team assessment of the 
patient and individualisation of the selection process is currently the 
best way to select suitable candidates in our opinion.
We had a high implantation success rate of 97% which compares 
well with more recently published figures of 90-96%.(9-11) Thirty-day 
mortality was also low at 7.1% which also compares well with 
published data of other groups, summarised in Figure 3.
Of the 2 procedural deaths we had, both were due to factors we 
could not predict and, in retrospect, the team’s opinion was that 
these complications were not predictable and we would not alter 
our management if given another chance. The patient who died 
due to thrombus on the valve (patient 58 discussed under Results) 
most likely had a vascular injury in the aorta with aortic tissue stuck 
on the device which then stimulated the thrombus formation. One 
year follow up was only available for the first 29 cases and here 
our figure of 14% mortality compares well to both cohorts of 
the PARTNER trial (24 and 30% mortality). Patient populations 
are likely to have differed significantly between these studies and 
direct comparisons are probably not accurate. One explanation for 
our good results may be that, because of the financial constraints, 
we were stricter with our selection of cases although this is not 
reflected in the log EuroSCORE risk prediction (26% in our cohort 
as compared to 29% in cohort A and 26% in cohort B of the 
PARTNER trial).(9,12)
Another major cause for morbidity and mortality is major vascular 
complications. We had a significant number of these but most were 
in the first half of our experience and since the introduction of 
the smaller calibre SAPIEN XT device, we only experienced one 
major vascular complication. Comparing our results to other groups 
is not easy, as the VARC definitions(8) were not available and 
therefore not used in most of these studies. Our figure of 9% major 
complications compares well to the 30% reported by the PARTNER 
trial.(9)
Post-procedural MR was significantly lower when considering the 
group as a whole, however in individual cases, the degree of MR 
may have worsened or improved and predicting this change was 
not possible. This is similar to the observations of others.(13) 
Although functional MR (as opposed to MR due to structural 
disease of the valve) could improve in theory, this has not been 
validated in studies.(14)
TAVI can be performed via the transfemoral route in patients who 
are awake. This makes the use of constant TEE monitoring virtually 
impossible. We feel that the benefit of having immediate access to 
an accurate diagnostic tool in case of a complication outweighs the 
risk of general anaesthesia. Furthermore, using a closure device for 
the femoral access site, adds to the cost of this procedure and we 
therefore continue to do surgical cut down in most transfemoral 
cases.
Technically, TAVI represents new challenges to both interventionists 
used to performing coronary interventions (with much smaller 
calibre devices) and surgeons not used to dealing with catheters 
and guide wires. A significant learning curve is therefore observed 
and despite our experience to date, this learning curve continues. 
Demonstrating a learning curve from the data is not simple as the 
numbers are small and outliers skew the data significantly. We 
could however show that most of the procedure-related para-
meters improved with experience (Table 3) but despite this, most 
of the patients who did not survive the hospitalisation, came from 
the second half of our experience. This illustrates how fragile these 
patients are and how unpredictable major complications can be. A 
learning curve was also demonstrated by numerous other groups 
with Webb demonstrating a fall in procedural mortality from 12 
to 3% in the transfemoral group.(15) This learning curve can only be 
maintained if the team performs adequate numbers of the 
procedure, something that will be very difficult in South Africa with 
its relatively small number of patients who can afford this costly 
procedure and resistance from some of the health care funders to 
support this new technology. Justifying such an expensive procedure 
in a country with a large proportion of poor people is diffucult and 
necessitates great care in patient selection to ensure that only 
deserving candidates are offered this procedure. One can only 
hope that the devices become more affordable in future and that 
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Shortcomings of the study
Although we turned a significant number of patients down for the 
procedure, this data was not collected prospectively and outcomes 
of these patients cannot be reported. A further study on the 
reasons for patients being turned may provide valuable information. 
Furthermore, our very low stroke rate may be explained by the fact 
that we did not follow all the patients up ourselves and there may 
have been under reporting. It has been shown repeatedly that most 
patients undergoing TAVI will have MRI visible micro-emboli to the 
brain, although clinically significant stroke is much rarer.(16,17.) Finally, 
this is only a report on short term data, reflecting our implantation 
success. Longer follow up is needed to further delineate these 
results.
CONCLUSIONS
With a multidisciplinary team approach and careful patient selection, 
TAVI can be performed by a high volume centre in South Africa 
with results comparable to international published outcomes. 
Mortality is better than predicted by EuroSCORE, underscoring the 
shortcomings of this scoring system. Patient selection remains 
difficult and further studies are needed to improve on this.
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